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CLINICAL RESEARCH ARTICLE
Dose-escalation trial of budesonide in surfactant for
prevention of bronchopulmonary dysplasia in extremely low
gestational age high-risk newborns (SASSIE)
Cindy T. McEvoy 1, Philip L. Ballard2, Robert M. Ward3, Joseph E. Rower3,4, Rajan Wadhawan5, Mark L. Hudak6,
Joern-Hendrik Weitkamp7, Julia Harris1, Jeanette Asselin8, Cheryl Chapin2 and Roberta A. Ballard2
BACKGROUND: Initial trials of lung-targeted budesonide (0.25 mg/kg) in surfactant to prevent bronchopulmonary dysplasia (BPD)
in premature infants have shown benefit; however, the optimal safe dose is unknown.
METHODS: Dose-escalation study of budesonide (0.025, 0.05, 0.10 mg/kg) in calfactatant in extremely low gestational age neonates
(ELGANs) requiring intubation at 3−14 days. Tracheal aspirate (TA) cytokines, blood budesonide concentrations, and untargeted
blood metabolomics were measured. Outcomes were compared with matched infants receiving surfactant in the Trial Of Late
SURFactant (TOLSURF).
RESULTS: Twenty-four infants with mean gestational age 25.0 weeks and 743 g birth weight requiring mechanical ventilation were
enrolled at mean age 6 days. Budesonide was detected in the blood of all infants with a half-life of 3.4 h. Of 11 infants with elevated
TA cytokine levels at baseline, treatment was associated with sustained decrease (mean 65%) at all three dosing levels. There were
time- and dose-dependent decreases in blood cortisol concentrations and changes in total blood metabolites. Respiratory
outcomes did not differ from the historic controls.
CONCLUSIONS: Budesonide/surfactant had no clinical respiratory benefit at any dosing levels for intubated ELGANs. One-tenth the
dose used in previous trials had minimal systemic metabolic effects and appeared effective for lung-targeted anti-inflammatory
action.
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INTRODUCTION
The survival of extremely low gestational age newborns (ELGANs)
has dramatically improved; however, bronchopulmonary dysplasia
(BPD) remains the most common morbidity of preterm birth.1
There are few effective and safe therapies to prevent BPD, which is
associated with significant complications in the neonatal intensive
care unit (NICU) and increased respiratory exacerbations, altered
pulmonary function, and neurodevelopmental abnormalities after
discharge.2–4 The pathogenesis for BPD is multifactorial, but an
important component is inflammation that results from intrauter-
ine events and postnatal hypoxia, hyperoxia, ventilator trauma
and/or infection in susceptible infants with immature lungs.5–7
One of the most consistent clinical factors associated with the
development of BPD is the need for mechanical ventilation, with
BPD occurring in >70% of ELGANs who require ventilation at
7−14 days of age.8
Systemic postnatal corticosteroids (PCS) are potent anti-
inflammatory agents and are one of the few therapies shown to
decrease the severity of BPD.9,10 Unfortunately, the heterogeneous
PCS treatment regimens that have been studied have not
established the optimal type of corticosteroid, optimal dosage,
or the optimal timing of initiation for the safe prevention of BPD.11
Early steroid treatment in conjunction with indomethacin treat-
ment for the patent ductous arteriosus (PDA) has been associated
with intestinal perforation.12,13 Systemic PCS, particularly dexa-
methasone, started at <8 days of life has been associated with
increased cerebral palsy.14,15
There is interest in the potential to deliver a postnatal steroid
topically to the lungs to improve the benefit:risk ratio. A trial of
tapering inhaled budesonide started at <12 h of life in infants
<28 weeks postmenstrual age (PMA) on any positive pressure
support showed a significant decrease in BPD at 36 weeks PMA,
but there was increased death in the treated group and no
information on systemic levels of budesonide.16 Yeh et al. have
conducted two unblinded pilot randomized trials of budesonide
(0.25 mg/kg) mixed in surfactant (Survanta) versus surfactant
alone administered soon after delivery to infants <1500 g with
severe respiratory distress syndrome (RDS). Both trials demon-
strated a significant decrease in the primary outcome of death or
BPD at 36 weeks PMA (p < 0.001) without adverse neurodevelop-
mental effects at 2 years of age.17–19 While these surfactant-based
trials are encouraging, further investigation is required to assure
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efficacy and safety and to establish the lowest effective dose.
There are preclinical data supporting the use of a much lower
dose of budesonide. For example, budesonide is five times more
potent than dexamethasone for suppression of chemokines in
fetal human lung explants;20 thus, treatment with 0.25 mg/kg
budesonide in surfactant would expose the lung to much higher
glucocorticoid levels than i.v. 0.25 mg/kg dexamethasone, an
effective systemic dose for prevention of BPD.
The objective of our study was to investigate the optimal dose
of budesonide suspended in surfactant and given intratracheally
to decrease the short-term respiratory support and pulmonary
inflammatory response of intubated ELGANs at risk for BPD. We
hypothesized that a lower dose than the previously administered
0.25mg/kg of budesonide would be equally effective in decreas-
ing short-term respiratory support and the inflammatory response
that contributes to BPD in intubated preterm infants.
METHODS
Study design and participants
The Steroids And Surfactant In ELGANs study (SASSIE) was a phase
I/II open label dose-escalation trial conducted at four US hospitals
(Clinicaltrials.gov: NCT 02907593). We treated eight intubated
ELGANs at risk for BPD with budesonide in surfactant at each of
three dosing levels: 0.025, 0.05, 0.10 mg/kg. The first eight enrolled
infants received the dose of 0.025mg/kg, the second eight
received 0.05 mg/kg, and the third group of eight received the
dose of 0.10 mg/kg. Inclusion criteria were infants with a
gestational age of 230/7 to 27
6/7 weeks who were mechanically
ventilated between postnatal days 3−14. Infants who had
received systemic steroids, or indomethacin, ibuprofen, or
acetominophen to treat a PDA ≤96 h before the enrollment
window ended, or had congenital malformations or chromosomal
anomalies were excluded. Case-matched infants who received
calfactant in the Trial of Late SURFactant (TOLSURF) served as the
control group.8 Controls were matched 2 to 1 for birth weight,
gestational age, sex, race, and initial respiratory severity score
(RSS=mean airway pressure × fraction of inspired oxygen).
The trial was conducted under the IND # 128102 for the
combined use of budesonide with the standard dose of calfactant.
The research protocol was approved by the Institutional Review
Boards of the participating institutions, and a parent of each infant
provided written informed consent. An independent data safety
monitoring board (DSMB) approved the protocol and met after
each group of eight patients reached 28 days of age to review
study progress and adverse events prior to approving progress to
the next dosing level.
The primary objective of the study was to determine the clinical
and anti-inflammatory efficacy by monitoring clinical outcome up
to 28 days of age, including RSS, and measuring tracheal aspirate
cytokine levels. By protocol, dose escalation was to be stopped if
the DSMB had safety concerns or after two dose levels that met
predefined efficacy criteria. Efficacy criteria included both clinical
criteria (five of eight infants extubated within 72 h of the first
study dose or after ≤3 daily treatments or one of several other
predefined clinical respiratory outcomes at 28 days of age
(see supplement) and evidence of anti-inflammation (≥50%
suppression of baseline tracheal aspirate interleukin-8 (IL-8) or
monocyte chemoattractant protein 1 (MCP1) at 24−72 h after the
initial dose of study medication).
We chose to start the dose escalation at 0.025mg/kg of
budesonide mixed in the standard dose of calfactant because data
from our fetal lung explant model20 had suggested this dose
should effectively suppress lung chemokine levels. The subse-
quent dosing levels of budesonide were 0.05 mg/kg and
0.10mg/kg. The research pharmacy at each institution prepared
the study medication as described in Methods Supplement.
Infants were dosed every 24 h if still requiring ventilation and
could receive up to five doses. Clinical guidelines for management
of ventilation and other patient care practices were developed
and approved by investigators.8
Materials and procedures
Tracheal aspirate (TA) samples were collected for markers of
inflammation. Dried blood spot (DBS) samples were collected for
the measurement of budesonide and untargeted metabolomics to
assess time- and dose-dependent changes in cortisol and other
biochemicals. TA were collected from the infant’s endotracheal
tube prior to and 12 h after the first study dose, just before each of
the subsequent doses, and 48 h after the fifth dose if the infant
remained intubated.8 DBS samples were collected at 15 min and
at 1, 4, and 24 h after the initial dose if the infant had a central line,
or 1, 4, and 24 h after the first dose if obtained by heel stick, and at
24 h after subsequent doses.21,22
Human chemokines CXCL-8/IL-8 and MCP-1/CCL2 were quanti-
fied in TA samples by enzyme-linked immunosorbent assay (ELISA)
(R&D Systems, Minneapolis, MN) that have intraassay variability of
5.8% each and interassay variability of 7.7% and 5.7%, respectively.
Both assays have a sensitivity range of 31−2000 pg/ml. Secretory
human IgA (sIgA) was used to normalize cytokine/chemokine data
and was measured by ELISA (Lifespan Biosciences, Inc., Seattle,
WA); intraassay variability of 5.8% and interassay variability of
6.0%, with a sensitivity range of 0.3−20 ng/µl). All samples were
assayed in duplicate as twofold dilutions. We used the Victor3
multichannel plate reader (Perkin Elmer, Waltham, MA) for
absorbance measurements.
Nine additional inflammatory mediators (IL-10, IL-12p70, IL-13,
IL-1β, IL-2, IL-4, TNF-α, INF-γ) were measured from TA samples
collected during the 0.1 mg/kg dose of budesonide; analysis was
by a multiplex assay as previously described.23,24
Budesonide concentrations were measured in DBS using a
validated liquid chromatography-tandem mass spectrometry (LC-
MS/MS) as previously described.22 The assay was linear between 1
and 50 ng/ml. Pharmacokinetic (PK) analysis of blood budesonide
was conducted using the noncompartmental analysis module in
Phoenix WinNonLin v6.4 (Certara, Princeton, NJ). An extravascular
dosing model was used to represent budesonide administration
via intratracheal instillation. The elimination slope was fit to the 1
and 4 h samples, and the linear up-log down calculation method
was used. Data below the limit of quantitation for the LC-MS/MS
assay (i.e. <1 ng/ml) were set as missing values.
Global metabolomic analysis using DBS was performed by
Metabolon Inc. using ultrahigh performance liquid
chromatography-tandem mass spectroscopy (UPLC-MS/MS). The
processing, assay and analysis procedures have been described in
detail.25
Statistical analysis
Data are presented as mean ± SD unless otherwise indicated.
Cytokine and chemokine data were analyzed using Mann−
Whitney test and analysis of variance (ANOVA) as appropriate.
Dose-dependent differences in systemic budesonide exposure
were assessed using ANOVA with Tukey post-hoc tests in
GraphPad Prism v8.1 (GraphPad Software, San Diego, CA). ANOVA
contrasts and Welch’s two-sample t test were used to identify
biochemicals that differed significantly between the dosing levels
of budesonide. Analysis by two-way ANOVA identified biochem-
icals exhibiting significant interaction and main effects for
experimental parameters of dose and time point.
RESULTS
Patients were enrolled between 3/11/2017 and 3/29/2018. A total
of 280 ELGANs were screened with 63 eligible and 25 consented
into the study (Fig. 1). One infant in the 0.1 mg/kg group had
consent withdrawn prior to treatment. An additional infant was
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enrolled at that dosing level to provide eight infants per dosing
level. Three dosing levels of budesonide in calfactant were
administered. Enrollment into the study was stopped after
completion of the 0.1 mg/kg dosing as no patient at any of the
three dosing levels had fulfilled the predefined efficacy criteria.
The mean gestational age, birth weight, and age at study
dosing of enrolled infants at the respective dosing levels are
presented in Table 1 along with the demographics of the 48
matched TOLSURF infants. All of the infants at the first two dosing
levels and six of eight at the third dosing level had received
surfactant within the first 24 h as per standard of care. All SASSIE
infants remained intubated after the first dose of study drug and
received two to five doses.
No infant at any of the three dosing levels achieved the primary
outcome of meeting both the predefined clinical respiratory
criteria and a >50% suppression of IL-8 or CCL2. There was a
significant decrease in RSS at 24 h after initial dosing for the
0.025mg/kg group and for the entire cohort (Table 1).
Table 2 shows the respiratory outcomes of SASSIE and TOLSURF
infants at 28 days and 36 and 40 weeks of PMA. All infants required
respiratory support at 28 days. Survival without BPD at 36 and
40 weeks was higher in the 0.025mg/kg dosing group than the 0.05
or 0.10mg/kg groups; however, the mean birth weight of the
0.025mg/kg group was 885 g compared to 704 and 651 g in the
other two groups. Overall, 3 of 24 (12.5%) in SASSIE vs. 2 of 48 (4.2%)
TOLSURF infants died and fewer infants in SASSIE survived without
BPD at 36 and 40 weeks (17% vs. 31 and 29% vs. 60%). No death or
serious adverse events were considered to be related to treatment.
Budesonide was detected in the circulation of all 24 subjects;
however, two (one in the 0.025mg/kg and one in the 0.05 mg/kg
dose cohorts) had insufficient data to calculate an elimination
slope based on 1 and 4 h data. All but two of the samples
collected at 24 h after the prior dose were below the limit of
quantitation (n= 71 of 73 collected samples). Figure 2a shows the
observed concentrations of budesonide in DBS at 0.25, 1, and 4 h
following the first dose for all three dosing cohorts.
The half-life of blood budesonide was short (3.4 h) and similar
between all dosing cohorts with mean peak concentrations for the
0.025, 0.05, and 0.10mg/kg dose cohorts of 7.7, 8.6, and 18.7 ng/
ml, respectively. When normalized for dose, the 0.05mg/kg and
0.10mg/kg cohorts had similar areas under the 24 h concentration-
time curve (AUC24), but both were significantly different from the
0.025mg/kg dose cohort (Fig. 2b, Table 3). Combined, these data
suggest that while systemic budesonide is eliminated at the same
rate independent of dose, the systemic absorption from the
intratracheal dose was not dose-linear in this cohort.
We assessed anti-inflammatory effects of budesonide in infant
lungs by the assay of TA levels of two chemokines.20 There was
adequate recovery of lung fluid for assay of IL-8, MCP1 and sIgA in
TA of 22 of the 24 enrolled infants. The ratio of the mean
chemokine value during treatment (from 12 h after the first dose to
24 h after the last dose) was determined, and infants designated as
apparent responders if there was >20% decrease compared to
predosing. The time course for IL-8 in two infants is shown in
Fig. 3a; infant 1 had a sustained decrease in IL-8 beginning 12 h
after the first dose with an increase at 48 h after the last dose,
whereas infant 2 had no consistent change in IL-8 levels until after
6 days of therapy. Infant 1 in this figure represented a responder,
while infant 2 was a nonresponder (Fig. 3a). Overall for the 22
infants, there were 11 apparent responders for IL-8 and 8 for MCP-1
(Fig. 3b), with a similar mean level of suppression noted for IL-8
(69 ± 13%) vs. MCP1 (60 ± 21%, NS).
We explored possible factors related to the chemokine response
to budesonide. Of interest, the predose levels of IL-8 and MCP1
varied widely (1096-fold and 3323-fold, respectively) and the
levels of the two chemokines were strongly correlated (r= 0.98,
p= 8−16). There was a strong association between predose levels
and the decrease during treatment, with higher baseline levels for
both IL-8 and MCP (~22-fold, p < 0.01) for responders compared to
280 ELGANS screened
over 12 months
63 Eligible
25 Consented into study
1 Withdrew consent in 
dosing level 3
8 At dosing level 1
8 At dosing level 2
9 At dosing level 3
103: Inclusion criteria not
met
78: Exclusion criteria met
36: Study on hold
10 Refused consent
35 Approached for
consent
4 In other studies; 6
parents LAR; 5 staff
unavailable; 13 other
Fig. 1 Enrollment of study participants. A total of 25 infants
consented into the study (one set of twins). One parent withdrew
consent in dosing level 3; therefore, eight infants were dosed at
each dosing level. Dosing levels of budesonide in calfactant were:
0.025 mg/kg; 0.05 mg/kg; 0.10 mg/kg. ELGANs extremely low gesta-
tional age newborns.
Table 1. Demographics and acute dosing data of the SASSIE and TOLSURF Reference Group.
Budesonide
dose (mg/kg)
n ASa (#) Gestational
age (weeks)
Birth
weight (g)
Male (#) Race/
ethnicityb
Age at first
dose (days)
Doses given
(mean, range)
RSS
Predosing
RSS 24 h
after
first dose
RSS 48 h
after
first dose
0.025 8 6 25.3 ± 1.6 885 ± 239 6 7/0/0/1 5.8 ± 3.2 3.9 (2−5) 3.9 ± 2.7 2.7 ± 1.5c 3.1 ± 2.1
0.05 8 7 25.3 ± 1.3 704 ± 196 2 6/1/0/1 8.0 ± 2.5 4.3 (3−5) 3.7 ± 0.9 3.6 ± 1.4 3.0 ± 1.9
0.10 8 7 24.4 ± 0.9 651 ± 100 4 7/1/0/0 5.6 ± 3.2 3.9 (2−5) 3.2 ± 2.3 2.5 ± 1.4 2.7 ± 1.4
All SASSIE
patients
24 20 25.0 ± 1.3 743 ± 204 12 20/2/0/2 6.5 ± 2.9 4.0 (2−5) 3.6 ± 2.0 2.9 ± 1.5d 2.9 ± 1.8
TOLSURF
controls
48 41 25.1 ± 1.2 742 ± 190 24 31/7/7/3 9.4 ± 2.7 3.9 ± 2.4 3.8 ± 1.8
TOLSURF controls were matched to surfactant-treated SASSIE infants by birth weight, gestational age, sex, race/ethnicity and initial RSS, in that order.
Mean ± SD unless otherwise noted.
AS antenatal steroids, RSS respiratory severity score (FiO2 × MAP).
aAS, any exposure to antenatal steroids.
bCaucasian/African American/Hispanic/other.
cp= 0.03 vs. predosing.
dp= 0.006 vs. predosing.
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nonresponders (Fig. 3c). There was a weak correlation between
blood budesonide level (at 4 h) and the change in TA IL-8 at 24 h
(r= 0.46, p= 0.04, n= 20, Fig. 4), indicating that responsiveness
was not strongly related to systemic budesonide levels. No
significant differences were observed in clinical parameters
comparing infants with suppression of IL-8 vs. those without
suppression, although more of the responders (8/11) than
nonresponders (4/11, p= 0.08) had a decrease in RSS with
budesonide treatment (Table 4).
Neither the number of responders, nor the level of suppres-
sion of IL-8 among responders, showed apparent dose-depen-
dency: 5 of 8 with 56 ± 13% suppression at 0.025 mg/kg, 2 of 7
and 84 ± 13% suppression at 0.05 mg/kg, and 4 of 7 and 79 ±
12% suppression at 0.1 mg/kg. Corresponding numbers for
MCP1 were 3/8, 2/7, and 3/7 with suppression of 46 ± 21%,
73 ± 13%, and 54 ± 35%, respectively. We used a multiplex
approach to assay an additional nine inflammatory mediators in
TA from infants receiving the 0.1 mg/kg dose (Table 5).23
Consistent decreases during budesonide treatment were
observed for all mediators (mean % suppression values ranging
from 51 to 79%) in three of the four infants with suppression of
IL-8. Baseline levels were higher for responders than nonre-
sponding infants for each mediator (range 1.8- to 5.0-fold) as
observed for IL-8 and MCP1 (5.8- and 5.7-fold) at this budesonide
dose. Overall, our results provide evidence for a strong anti-
inflammatory response in the lung for some, but not all, infants
that is independent of the budesonide dose between 0.025 and
0.1 mg/kg and is related to elevated inflammatory status in the
lung at baseline.
We identified eight infants in the TOLSURF cohort who received
late surfactant, but not systemic PCS, and who had five TA
samples collected over a 9 ± 2-day period. In this group,
comparing mean levels for samples 2−5 with sample 1, there
was a consistent suppression of IL-8 and MCP1 in 3 and 1 infants,
respectively, with suppression ranging between 54 and 69%. For
the value for the group. To examine systemic responses to
budesonide, we performed untargeted metabolomics on SASSIE
DBS.25 A total of 829 named biochemicals were detected in 121
dried blood spots from 23 infants over 7 time points (15 min−96 h
post 3 infants with declining chemokine levels over time, baseline
values (sample 1) were near the median treatment initiation).
There was a statistically significant, time-dependent decrease in
cortisol for infants receiving 0.05 and 0.1 mg/kg budesonide, with
decreased levels occurring at 4 h and mean suppression of 52%
and 75%, respectively, at 24 h (Fig. 5a). By contrast, blood cortisol
did not change significantly for the group of infants treated with
0.025mg/kg budesonide.
To evaluate global systemic metabolic responses, the number of
significant (p < 0.05) changes (decreased or increased) were
determined for each time point compared to the 15-min value
(Fig. 5b). There was a time-dependent increase in number of
changes at all three doses, with a similar relatively low level of
changes (<40) in the first 24 h, and a dose-dependent response at
later time points; at 96 h, the number of metabolite changes were
48, 127, and 260 at 0.025, 0.05, and 0.1 mg/kg, respectively,
representing 5.8%, 15.3%, and 31.4% of the known biochemicals
detected. These results indicate that intratracheal budesonide:
surfactant treatment, at the doses and frequency used, has an
Table 2. Infant outcomes of the SASSIE and TOLSURF Reference Group.
Budesonide dose
(mg/kg)
n Death at <28 days Respiratory support at
28 days (%)
Survival without BPD at
36 weeks (%)
Survival without BPD at
40 weeks (%)
0.025 8 0 100 38 63
0.05 8 0 100 0 13
0.10 8 3 100 13 13
All SASSIE patients 24 3 100 17 29
TOLSURF patients 48 2 100 31 60
BPD bronchopulmonary dysplasia.
40
0.025 mg/kg
0.05 mg/kg
0.10 mg/kg
30
20
10
0
2.5
2.0
1.5
1.0
0.5
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0.4
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b
Fig. 2 Budesonide pharmokinetics in dried blood spots (DBS).
a Concentrations at 0.25, 1, and 4 h following the first dose in the
0.025mg/kg (unfilled), 0.05 mg/kg (light gray filled), and 0.10 mg/kg
(dark gray filled) dose cohorts. Whiskers represent minimum and
maximum concentrations, boxes represent the 25th and 75th
percentile, the central line represents the median, and the point
represents the mean value. b Dose-normalized Cmax (gray) and
AUC24 (black) for the three dosing cohorts. Relative to the
administered dose, systemic budesonide exposure at the
0.025mg/kg dose is greater than that observed for the other two
dosing cohorts.
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approximately linear dose−response impact on blood biochem-
icals, consistent with extra-pulmonary effects of circulating steroid.
DISCUSSION
We performed a dose-escalation study of budesonide in calfactant
given intratracheally to ELGANs still requiring mechanical ventila-
tion at 3−14 days of age starting at one-tenth the dose used in
previous studies.18,19 Although most infants had a decrease in RSS
following treatment, there were no differences between dosing
groups in clinical respiratory outcomes at 28th day. BPD at 36 or
40 weeks PMA was less common in infants in the 0.025mg/kg
group; however, these infants had a higher mean birth weight
than the other two groups. Only half of the infants had evidence
of increased inflammatory markers in TA at initiation of the study,
and these infants had a similar decrease in levels of the two
cytokines with treatment at all three dosing levels. There was a
dose-dependent increase in both suppression of blood cortisol
and in the number of alterations in levels of other blood
metabolites indicating systemic absorption and effects of the
corticosteroid. These results suggest that intratracheal budesonide
reduces lung inflammation only in infants who have elevated
inflammatory status, and that this effect occurs at the lowest dose
tested (0.025 mg/kg), which has minimal systemic metabolic
effects and can be safely repeated if the infant remains intubated.
Survival without BPD for SASSIE infants was lower than for the
historical matched TOLSURF cohort, which may reflect in part
benefit from inhaled nitric oxide in nonwhite infants.26 The
apparent lack of clinical benefit is also in contrast to the two pilot
RCTs of Yeh et al., in which significantly fewer infants in the
treated group (single dose of 0.25 mg/kg budesonide in Survanta)
had BPD at 36 weeks PMA.18,19 There are several possible
explanations for this difference. Our study did not have concurrent
controls nor was it powered to detect significant differences in
clinical outcomes. Importantly, in the Yeh studies,18,19 infants were
enrolled within the first 24 h of receiving FiO2 > 0.6 and were
mechanically ventilated whereas infants in SASSIE were only
enrolled if they required mechanical ventilation between post-
natal days 3 and 14 and were therefore in the highest risk group
(>70%) for BPD.8 The lack of apparent clinical response may also
reflect differences in the patient populations. The infants in Yeh’s
studies were more mature and larger than the infants in SASSIE. In
SASSIE, infants treated within 96 h of dosing for a PDA were
excluded to minimize any potential interactions with study
medication and this may have biased results.
Yeh et al. previously described the pharmacokinetics of
budesonide in ten preterm neonates (<1500 g at birth) following
intratracheal instillation of 0.25 mg/kg budesonide.18 The
observed elimination half-life (3.4 h) in our study was similar to
the Yeh study (4.1 h). The AUC reported in Yeh’s study (AUC0−8=
115.7 ng × h/ml) extrapolates to an AUC24 of approximately
200 ng × h/ml. When normalized for dose, this value is similar to
the AUC24 observed for the 0.10 mg/kg cohort in our study. These
kinetics support daily treatment to sustain elevated blood
budesonide. Concentrations of budesonide in human lung are
not known, but in lambs levels in lung tissue decrease to 0.4% of
the initial dose at 24 h.27
The Yeh study observed a peak concentration of approximately
20 ng/ml at 30min after dose. This peak concentration is similar to
the Cmax of 18.7 ng/ml at 15 min post dose from a lower dose
(0.10 mg/kg) in our study, suggesting a ~2.5-fold difference in
observed Cmax between the studies.
18 From the data collected, it is
unclear whether the difference in Cmax is due to a difference in
absorption secondary to the surfactant used (Survanta in Yeh’s
trial, Calfactant in our study), the gestational weight and/or age
differences between study populations, the difference between
samples collected at 15 and 30min post dose, and/or methodo-
logic differences.
The plasma concentrations of budesonide in infants can be
compared to those achieved with antenatal betamethasone for
enhancing fetal maturity and postnatal dexamethasone given for
prevention of BPD. In this calculation, we convert corticosteroid
levels to cortisol equivalents using factors of 7-fold for betametha-
sone and dexamethasone and 50-fold for budesonide based on
receptor affinity and dose−response data from cultured human fetal
lung.20,28 Mean peak concentrations as cortisol equivalents are: 4 µg/
dl for normal 25-week human fetus, 15 µg/dl in cord blood after
intramuscular antenatal betamethasone, 140 µg/dl with 0.25mg/kg
postnatal dexamethasone, and 72 µg/dl after 0.1mg/kg intratracheal
budesonide.29–31 Thus, both postnatal dexamethasone and bude-
sonide at current doses transiently expose the infant to plasma
concentrations considerably greater than those occurring with
physiologic stress in the newborn (e.g., RDS ~15 µg/dl). Risks for the
infant associated with these higher exposures may depend on both
the concentration of corticosteroid and duration of exposure.
Treatment with budesonide in surfactant primarily targets lung
inflammation, although it is possible that local effects are
modulated by systemic exposure to budesonide. To assess local
effects of budesonide, we measured two chemokines in lung fluid
that are chemoattractants for neutrophils (IL-8) and lymphocytes
(MCP1). Both mediators are produced in human fetal lung and are
suppressed by glucocorticoids in explant culture.20 Levels of the
two chemokines were strongly correlated at both baseline and
after treatment, which is consistent with a previous observation
for multiple cyto/chemokine levels in TA32 and indicate that our
findings likely reflect the overall inflammatory status in the lung.
Apparent suppression of IL-8 and MCP1 was observed in half of
the SASSIE infants and was strongly associated with higher
Table 3. Pharmacokinetics of the budesonide dosing cohorts.
Budesonide dose (mg/kg) ke Half-life Cmax Cmax/Dose AUC24 AUC24/Dose
1/h h ng/ml (ng/ml)/(mg/kg) (ng × h/m) (ng × h/ml)/(mg/kg)
0.025 0.224 (40%) 3.78 (57%) 7.70 (57%) 0.308 (57%) 39.4 (39%) 1.58 (39%)
0.05 0.242 (26%) 3.20 (37%) 8.60 (71%) 0.172 (71%) 37.2 (57%) 0.744 (57%)
0.10 0.268 (43%) 3.20 (56%) 18.7 (35%) 0.187 (35%) 73.5 (44%) 0.735 (44%)
ANOVA p value 0.71 0.77 0.001 0.08 0.01 0.002
Tukey p value 0.025 vs. 0.05 0.95 0.11 0.99 0.007
0.025 vs. 0.10 0.002 0.15 0.03 0.004
0.05 vs. 0.10 0.004 0.97 0.02 0.99
Data are calculated mean (%CV) pharmacokinetic parameter values for the three dose cohorts, as well as the p values from the ANOVA and Tukey post-hoc
analyses.
ke elimination rate, Cmax maximum concentration, AUC24 area under the concentration 24-h time curve.
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baseline levels, suggesting that inflammation is not a universal
feature of lung injury in the first week and that benefit from
budesonide (or any glucocorticoid) will only occur in selected
infants with elevated inflammatory status.
The global blood metabolomic data demonstrated a clear
dose−response association with budesonide. At 0.025mg/kg
budesonide, there was a small suppression of cortisol, and limited
changes in other biochemicals, and both responses increased
progressively with higher doses. This pattern contrasts with
suppression of TA chemokines where no differences were
apparent between doses, and is consistent with elevated levels
of budesonide within the lung, compared to systemic levels, with
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Table 4. Characteristics of infants based on apparent suppression of
IL-8 by budesonide treatment.
Responders
(n= 11)
Nonresponders
(n= 11)
p
Gestational age (wk) 25.0 ± 1.3 25.2 ± 1.3 0.62
Birth weight (g) 740 ± 192 788 ± 247 0.62
Sex (m/f ) 5/6 7/4 NS
Race (c/aa/h/o)a 6/1/3/1 7/1/3/0 NS
Doses budesonide 4.5 ± 1.1 3.8 ± 1.4 0.23
Budesonide dose
(mg/kg)
0.06 ± 0.04 0.06 ± 0.03 1.0
Blood budesonide at
4 h (ng/ml)
4.9 ± 2.1 3.2 ± 2.5 0.10
RSS at enroll 3.6 ± 1.9 3.0 ± 1.3 0.38
RSS decrease >0.2 at
24 h
8 4 0.08
Data are mean ± SD and p by unpaired t test.
RSS respiratory severity score (mean airway pressure × FiO2).
aCaucasian/African American/Hispanic/other.
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intratracheal delivery. Thus, our results suggest that the best
benefit:risk ratio of budesonide:surfactant therapy occurs at doses
of 0.025/0.05 mg/kg, which are five- to tenfold lower than used
currently in clinical studies.
Strengths of our study include the study population of
intubated ELGANs who are at high risk for BPD, the dose-
escalation study design, and measurement of multiple biomarkers
for both lung anti-inflammatory and systemic effects of budeso-
nide. Previous studies33,34 using surfactant-antibiotic mixtures had
demonstrated interactions between these agents; however, we
recently reported no apparent adverse effect of budesonide on
calfactant activity in vitro nor an effect of calfactant on
budesonide action.20 An important limitation of our chemokine
data is the possibility that, in some infants, the lower chemokine
levels during budesonide treatment reflected decreasing inflam-
mation independent of glucocorticoid exposure as observed in
some of the TOLSURF infants. However, the pattern of suppression
observed with budesonide, beginning in most infants 12 h after
the first dose and sustained during the treatment period, is
consistent with suppression in response to budesonide. Also, we
used sIgA to normalize chemokine levels to volume of lung fluid in
the TA sample; it is possible that sIgA production in vivo varied
during the collection period, which would introduce variability in
the chemokine data. A limitation of our pharmacokinetic analysis
is the absence of data after the 4 h time point; however, our half-
life value was similar to that reported by Yeh et al., supporting the
accuracy of our PK results.18
The dose-escalation study design limited the number of infants
studied at each dosing level. Also, concurrent controls were not
included in the study design, for ethical reasons, and the matched
historical controls received inhaled NO and were not evaluated for
other potential confounding factors such as chorioamnionitis.
Earlier dosing, longer dosing, or the use of noninvasive
approaches to surfactant delivery may result in different clinical
outcomes. The original study design included a fourth dosing level
(which would have been either 0.20 mg/kg or 0.25 mg/kg
contingent on the response to dosing level 3), which may have
provided more detail regarding clinical and anti-inflammatory
response to the combination of the study medications. However,
we decided not to continue enrolling the infants in this study after
the first three dosage levels failed to show clinical benefit. Given
that aggressive use of noninvasive mechanical ventilation has not
reduced the incidence of BPD, that BPD may develop in ELGAN
babies with little clinical initial evidence of lung disease, and that
inflammation associated with BPD worsens over the first weeks
after birth, the question of whether serial instillation of
budesonide suspended in surfactant reduces BPD remains an
unanswered question. Future randomized trials in ELGANs at high
risk for BPD should require treatment over the biological period of
risk to assess efficacy and safety in a fair way.
Our results do not support the “late” treatment of intubated
ELGANs with a regimen of budesonide in surfactant at the three
dosages we tested, but do provide important insights into blood
budesonide concentrations, lung anti-inflammatory effects and
potentially global metabolomics effects that are critical to the
consideration of treatment with this combination of medications.
We were not powered to investigate association of inflamma-
tion with near-term pulmonary outcome, but we suggest that
measurement of TA inflammatory mediators would be informative
in future trials of PCS therapy.
In conclusion, assuming that the respiratory benefits of PCS
therapy primarily relate to anti-inflammatory effects in the lung,
our results suggest that one-tenth the budesonide dose in
Table 5. Tracheal aspirate levels of additional inflammatory mediators
for infants with apparent response to 0.1 mg/kg budesonide.
Cyto/
chemokine
Number of infants
with suppression
(n= 7)
% suppression
(mean ± SD)
Predose level
(suppress/no
suppress)
IFN-γ 3 68 ± 18 1.9
IL-10 3 72 ± 21 3.7
IL-12p70 3 69 ± 13 3.0
IL-13 3 69 ± 3 5.0
IL-1β 3 64 ± 19 4.9
IL-2 3 72 ± 19 2.0
IL-4 3 65 ± 18 1.8
IL-6 3 56 ± 18 4.3
TNF-α 2 51 ± 42 3.6
IL-8 4 79 ± 12 5.8
MCP1 3 54 ± 35 5.7
Total 65 ± 9 3.8 ± 1.5
Data are by multiplex assay for the first nine mediators and by ELISA for IL-
8 and MCP1; suppression occurred in the same infants for each mediator.
Apparent suppression was assigned for infants with consistently lower
values during treatment compared to predosing with a mean value of
>20%.
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surfactant used in previous studies is sufficient to reduce
inflammation with minimal systemic effects even with repeated
treatment. Additional trials of this promising lung-targeted
approach to preventing BPD are needed using lower doses of
budesonide with further study of efficacy, safety, inflammatory
markers and endocrine and metabolic responses.
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